Humacyte, Inc. Retained Earnings
Humacyte, Inc. (HUMA) had Retained Earnings of -$781.27 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-12
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$781.27M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$744.47M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$726.85M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$702.04M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$781.27M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | -$744.47M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | -$726.85M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | -$702.04M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$684.53M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | -$646.88M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | -$686.01M 10-K · filed 2026-03-27 | |
| 2024-09-30 | -$665.08M 10-Q · filed 2024-11-08 | |
| 2024-06-30 | -$625.87M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | -$569.21M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | -$537.31M 10-K · filed 2025-03-31 | |
| 2023-09-30 | -$512.21M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | -$486.21M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | -$463.51M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | -$426.54M 10-K · filed 2024-03-28 | |
| 2022-09-30 | -$422.82M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | -$397.54M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | -$434.40M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | -$414.57M 10-K · filed 2023-03-24 | |
| 2021-09-30 | -$457.16M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | -$7.73M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | -$8.02M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | -$388.10M 10-K · filed 2022-03-29 | -$233.33K 10-K · filed 2021-02-16 |
| 2020-09-30 | -$40.95K 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |